Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer

Neoadjuvant therapy (NAT) is increasingly applied in pancreatic ductal adenocarcinoma (PDAC); however, accurate prediction of therapeutic response to NAT remains a pressing clinical challenge. Cancer-cell-derived sialylated immunoglobulin G (SIA-IgG) was previously identified as a prognostic biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Ming, Shoucair, Sami, Liao, Quan, Qiu, Xiaoyan, Kinny-Köster, Benedict, Habib, Joseph R., Ghabi, Elie M., Wang, Junke, Shin, Eun Ji, Leng, Sean X., Ali, Syed Z., Thompson, Elizabeth D., Zimmerman, Jacquelyn W., Shubert, Christopher R., Lafaro, Kelly J., Burkhart, Richard A., Burns, William R., Zheng, Lei, He, Jin, Zhao, Yupei, Wolfgang, Christopher L., Yu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389326/
https://www.ncbi.nlm.nih.gov/pubmed/36799816
http://dx.doi.org/10.1097/JS9.0000000000000200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389326/
https://www.ncbi.nlm.nih.gov/pubmed/36799816
http://dx.doi.org/10.1097/JS9.0000000000000200

Ejemplares similares